A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease

• Status: Completed
• Trial end date: 2010-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Determine the predictive value of CARDIOLITE® rest and stress myocardial perfusion imaging (MPI) to define a pediatric population with Kawasaki Disease (KD) at high and low risk of developing cardiac events.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lantheus Medical Imaging
• Treatments: Technetium Tc 99m Sestamibi

Criteria

Inclusion Criteria:

• Males or females between 4 and 16

• Meet the epidemiological definition of Kawasaki Disease or have a diagnosis of incomplete KD, including evidence of coronary artery disease as determined by their physician.

• Be able to exercise adequately to achieve 85% age predicted maximum heart rate

Exclusion Criteria:

• Terminal illness where expected survival is < 6 months